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Patient Advocacy in Research
Merely an Afterthought?
Musa Mayer
AdvancedBC.org, New York, USA
In 20 years of breast cancer advocacy, I’ve
witnessed major changes in attitude toward ad-
vocates on the part of basic researchers, clinical
investigators, and others involved with the science
of the disease.
Not so long ago, even a seat at the table –
much less a vote –was hard to come by. Advocate
presence was met with puzzlement, if not outright
resistance. How could we possibly understand the
complex scientific issues under discussion? What,
exactly, was our expertise?
Within the space of a very few years – not co-
incidentally with the increase in advocate-driven
research funding –waves of change began to wash
away this resistance. Appreciation for our fund-
raising efforts, mixed with grudging recognition
that people who actually live with a disease have
useful perspectives, were contributing factors. In
the wake of the 1970s and the women’s health
movement, medical paternalism was relaxing its
grip, and a new generation embraced the patient-
doctor relationship as a partnership of equals. In
the late 1980s, AIDS activists demonstrated the
power of organized pressure on access and policy
when lives were at stake. In the early 1990s, the
Internet began to connect and empower a steady
stream of newly informed patients.
It was in just such an online community, the
first breast cancer mailing list, that my own ad-
vocacy was born, from a desire to ‘pay forward’
the information and support offered me when
I was diagnosed. What began as a small, personal
ripple expanded outwards as I recovered from
treatment and moved from helping the members
of my support group to reaching out to women in
emerging organizations and communities, then to
all women with breast cancer.
I joined with other advocates. Not satisfied with
offering only emotional support, we called for
better, less toxic treatments available to everyone.
The standard of care seemed harsh and crude.
Some referred to chemotherapy, surgery, and radia-
tion as ‘poison, slash, and burn.’ Rejecting the
metaphors of war, we called for gentler, targeted
therapies with less ‘collateral damage.’ To accom-
plish this, more and better research was needed.
We were not content with just handing over the
research funds. We looked with suspicion at the
minor progress made in Nixon’s war on cancer1
and began to raise questions about the direction
of cancer research, and the lack of collaboration
and support for novel ideas. Funded through the
efforts of advocates, programs such as the US
Department of Defense Breast Cancer Research
Program[1] were born.
In the years since, the presence of advocates has
become commonplace in the world of cancer re-
search. We sit on US FDA advisory committees
as voting members, on Institutional Review Boards
(IRBs), and data safety monitoring boards for
clinical trials. We serve on Specialized Programs
of Research Excellence (SPOREs) and in the
1 When American President Richard Nixon signed the National Cancer Act into law in 1971, he said, ‘‘The time
has come in America when the same kind of concentrated effort that split the atom and took man to the moon
should be turned toward conquering this dread disease.’’
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Cooperative Groups.2 We rate grant proposals
in study sections, and help determine research
priorities. We speak at conferences, and are co-
authors of papers, posters, and abstracts. We offer
input to industry about trial design and enrol-
ment, drug safety, and access to new therapies
in the pipeline. Our activism runs both ways. By
translating what we learn of the research back to
the patients we serve, we help them to make
better, more informed treatment decisions.
In preparing this article, I shared my concerns
with Patient Advocates in Research (PAIR), a
long-standing mailing list. The flood of responses
spoke candidly about our difficulties, as well as
our roles and strengths.
Several emphasized the important role we play
in encouraging collaboration rather than competi-
tion among researchers, helping them to concentrate
more on meaningful goals, and less on professional
and career concerns. This is no easy task. It is the
nature of research to ‘‘meander from one disparate
place to another,’’ explains Deborah Collyar,
President and co-founder of the PAIR mailing
list, ‘‘which keeps the focus on the individual PIs
[Principle Investigators] who compete with each
other for grants. It’s like a game of musical chairs.’’
To make an impact, she suggests, ‘‘We have to
speak up, and remind them to act like big boys
and girls to get something done.’’
Colorectal cancer advocateKateMurphy agrees,
‘‘Research can answer interesting but irrelevant
questions, provide statistically significant but clin-
ically insignificant resultsy but in the end, does
it matter to patients? Researchers can lose sight of
the real goals, and we can keep them honest.’’
The very presence of advocates can make a
difference. ‘‘Not only does my face and my story
inject reality into the cancer research enterprise,
it seems to add some sense of urgency,’’ says
Murphy. ‘‘We need to get the job done now
without quibbling and without egos.’’
Sometimes, advocates are the only ones who
bring a real-world perspective to research discus-
sions, says breast cancer advocate Cheryl Jernigan.
‘‘We’ve got to get beyond incremental steps that
simply add to already unsustainable growing
healthcare costs, to research that makes a sub-
stantial difference in the length and quality of life,
that will be accessible in the community setting
and not break the bank.’’
An education in the language and methods of
science is critical. Trained advocates challenge
biases researchers may have had, by presenting
themselves as thoughtful and intelligent peers and
colleagues, well versed in the research process.
But still they are underutilized at times, and un-
sure of their roles. ‘‘Most researchers who have
engaged with us seem to really appreciate our
involvement,’’ says Jernigan, ‘‘but don’t really
know when, where, or how to engage us, and we
don’t always know what it is we can do.’’
Joyce Graff, advocate for patients with Von
Hippel-Lindau (VHL) disease, a genetic blood ves-
sel malformation, has experienced little support
from the SPORE on which she serves: ‘‘Periodi-
cally, they will turn to me in a meeting and ask
whether a proposed clinical trial design will ap-
peal to patients.’’ But her opinion is solicited only
after trial proposals and informed consent docu-
ments have been submitted to the IRB.
Being invited to endorse, or recruit for, re-
search studies without participating in their crea-
tion is a familiar complaint. I’m not alone in
having been invited to join steering committees
for registries and clinical trials only after the im-
portant initial decisions are made. Substantive
roles for advocates can be hard to come by.
But when we are brought in early in the pro-
cess, we can make a genuine contribution,
Collyar feels, ‘‘We help them think about how
they will actually implement the trial and how to
reach as broad an audience as possible, ethnically
speaking, as well as eliminating bogus eligibility
requirements.’’
Many of us have experienced last-minute calls
and emails from researchers a day or two before
2 Part of the US National Cancer Institute’s Translational Research Program, SPORE grants are collaborative,
interdisciplinary groups of preclinical and clinical researchers. The NCI Cancer Trials Cooperative Group pro-
gram involves networks of researchers, cancer centers, and community physicians in the US, Canada, and Europe
who jointly conduct large clinical trials following the same protocol.
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grant proposals are due. Clearly, the PI has dis-
covered that advocate involvement is required
and is scrambling to find someone. We become
an obstacle to be surmounted, not a resource to
be used.
I’ve been fortunate enough to have also had
the opposite experience. Involved in a major re-
search grant to study brain metastases in breast
cancer,[2] my input, and that of other advocates,
has been invited and welcomed at all stages of
planning and implementation, with the complete
confidence and trust of an enlightened PI who
has worked with advocates for years.
Central to drug development, regulatory poli-
cy is also of intense interest to advocates. I first
served as a voting Patient Representative[3] on the
FDA’s Oncologic Drugs Advisory Committee a
decade ago. At the open public hearings, diverse
advocacy perspectives are on display, ranging from
passionate pleas for access to calls for tightened
regulations. While some view the agency as a
bureaucratic and unfeeling barrier to access, the
FDA’s mandate always made sense to me. I too
was concerned about risks and benefits of new
treatments, about levels of evidence and adequate
proof of safety and efficacy. Having witnessed the
rise and fall of bone marrow transplants in breast
cancer, I knew how catastrophic the premature
adoption of unproven therapies could be.
As a graduate of Project LEAD, the National
Breast Cancer Coalition’s science training course,[4]
I fervently believed that advocates needed to un-
derstand the research process, and to be able
to look beyond immediate needs to what would
offer current and future benefit for all patients.
To that end, I co-developed a free, online training
curriculum for theUSCochraneCenter in evidence-
based healthcare specifically for advocates.[5]
If advocates only understood the research
process, I reasoned, they would surely take more
nuanced, thoughtful positions on issues of evi-
dence and access. But reason trumps emotion
only rarely when lives are at stake, and desper-
ation fuels inflated hopes for treatment efficacy.
Described by ethicist Rebecca Dresser as ‘‘advo-
cacy’s emphasis on the bright side of medical re-
search,’’[6] this unwarranted optimism has the
potential to increase demand for unproven treat-
ments, and to make it harder to recruit definitive
studies. Patient bitterness and public disillusion-
ment with the research enterprise are sure to follow.
Science is hard. ‘‘Most of our experiments
fail,’’ a researcher I work with reminded me re-
cently. For advocates, removing the blinders of
wishful thinking, replacing them with a clear-
eyed, cautious view of scientific research, is so-
bering but necessary. To do so while maintaining
a hopeful stance with the patient communities we
represent is harder still. But then, no one prom-
ised the truth would be easy.
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